my personal edition > multiple sclerosis > news


  E-Mail this DGNews to a colleague

DGNews

Anti-Epileptic Drug Levetiracetam Also Effective in Controlling Debilitating Symptom of Multiple Sclerosis

DALLAS, TX -- December 16, 2003 -- A drug proven effective in controlling epileptic seizures also appears to treat one form of spasticity in multiple sclerosis patients, report researchers at UT Southwestern Medical Center at Dallas. Spasticity is a key factor in many MS patients' loss of the ability to walk.

A study published in the December issue of Archives of Neurology and currently available online shows that levetiracetam reduced phasic spasticity, which is marked by spasms and painful muscle cramps, in 100 percent of patients in a small clinical study.

"It's amazing how many MS patients can't walk, can't move, and you treat their spasticity and they're fine," said Dr. Kathleen Hawker, assistant professor of neurology at UT Southwestern and lead author of the study. "What's nice about these drugs is that they also work for nerve pain, which in turn improves the patient's mood, so we can use one drug for three things instead of prescribing pain killers and antidepressants in addition to the spasticity therapies."

Spasticity is often seen in patients with MS and amyotrophic lateral sclerosis (ALS), as well as after a stroke or spinal-cord injury. It can lead to loss of balance, increased risk of falls, pain, fatigue, and walking difficulties.

Drugs currently used to treat spasticity may cause memory problems, weakness and lethargy in some patients.

"We're trying to look at medicines that can be used for multiple symptoms so we don't get into a lot of drug interactions," Dr. Hawker said. "If we can get the same results with a better-tolerated drug, that's great for our patients."

Researchers examined the histories of 11 patients treated with levetiracetam between January 2001 and June 2002 for MS-related spasticity at Southwestern Medical Center. The patients were treated with levetiracetam for one to four months, with dosages starting at 250 milligrams per day and increasing to 3,000 mg per day. Researchers found that leviteracetam decreased phasic spasticity in patients taking the drug alone as well as in those who took it in combination with other therapies for spasticity. Tonic spasticity, which produces stiffness, did not improve. Overall, the clinical investigators found the side effects of levetiracetam to be generally mild, Dr. Hawker said.

Multiple sclerosis is the most common disabling disease of young people, ages 18 to 45, and affects 350,000 people in the United States. Symptoms of the disease are unpredictable, vary by individual, and often come and go. While one patient may experience severe vision problems, another may have abnormal fatigue. Other symptoms include loss of balance and muscle coordination, slurred speech, tremors, stiffness, and bladder problems.

Dr. Elliot Frohman, head of UT Southwestern's multiple sclerosis program and associate professor of neurology and ophthalmology, and Dr. Michael Racke, associate professor of neurology and in the Center for Immunology, also participated in the study, which was partially funded by UCB Pharma, Inc.


SOURCE: UT Southwestern Medical Center

E-Mail this DGNews to a colleague

To print, use this version